Acid Sphingomyelinase Deficiency (ASMD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Acid Sphingomyelinase Deficiency (ASMD) Market Outlook

Thelansis’s “Acid Sphingomyelinase Deficiency (ASMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acid Sphingomyelinase Deficiency (ASMD)   treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Acid Sphingomyelinase Deficiency (ASMD) Overview

Acid sphingomyelinase deficiency (ASMD), also known historically as Niemann-Pick disease types A, A/B, and B, is a lysosomal storage disease stemming from inadequate activity of the enzyme acid sphingomyelinase (ASM). This insufficiency results in the buildup of varying sphingomyelin levels within the body. ASMD is an inherited disorder caused by genetic variations that modify specific bodily processes, leading to the onset of the disease. The gene responsible for ASMD is referred to as SMPD1. This condition manifests with foam cell infiltration across different tissues, lipid storage, and a range of clinical symptoms that might overlap. Among these symptoms, pulmonary insufficiency, hepatosplenomegaly, and neurodegeneration stand out. The clinical presentations of ASMD serve as the primary indicators for differentiating this disease, which presents itself as a multi-organ disorder. While hepatosplenomegaly and lung dysfunction are prevalent features in ASMD, ASMD A also involves the central nervous system. ASMD A progresses rapidly and is frequently fatal within the initial years of life. On the other hand, ASMD B demonstrates a slower progression, featuring milder symptoms and often allowing patients to reach adulthood. The diagnosis of ASMD is established by identifying biallelic pathogenic variants in the SMPD1 gene using molecular genetic testing. Additionally, the assessment of residual acid sphingomyelinase enzyme activity, measuring less than 10% of controls, in peripheral blood lymphocytes or cultured skin fibroblasts confirms the diagnosis. Enzyme Replacement Therapy (ERT) utilizing Olipudase alfa (Xenpozyme®) effectively mitigates sphingomyelin accumulation in organs such as the lung, liver, and spleen, excluding the central nervous system.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Acid Sphingomyelinase Deficiency (ASMD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034